Advertisement
Advertisement

ABCL

ABCL logo

AbCellera Biologics Inc. Common Shares

5.62
USD
Sponsored
-0.75
-11.77%
Jun 05, 15:56 UTC -4
Closed
exchange

After-Market

5.78

+0.16
+2.90%

ABCL Earnings Reports

Positive Surprise Ratio

ABCL beat 10 of 22 last estimates.

45%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$8.01M
/
-$0.17
Implied change from Q1 26 (Revenue/ EPS)
-3.72%
/
+21.43%
Implied change from Q2 25 (Revenue/ EPS)
-53.14%
/
+41.67%

AbCellera Biologics Inc. Common Shares earnings per share and revenue

On May 11, 2026, ABCL reported earnings of -0.14 USD per share (EPS) for Q1 26, beating the estimate of -0.19 USD, resulting in a 29.86% surprise. Revenue reached 8.31 million, compared to an expected 5.97 million, with a 39.20% difference. The market reacted with a +0.19% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.17 USD, with revenue projected to reach 8.01 million USD, implying an increase of 21.43% EPS, and decrease of -3.72% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Greenwich LifeSciences, Inc.
Report Date
Jun 01, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.57
Surprise
-77.70%
FAQ
For Q1 2026, AbCellera Biologics Inc. Common Shares reported EPS of -$0.14, beating estimates by 29.86%, and revenue of $8.31M, 39.2% above expectations.
The stock price moved up 0.19%, changed from $5.24 before the earnings release to $5.25 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 7 analysts, AbCellera Biologics Inc. Common Shares is expected to report EPS of -$0.17 and revenue of $8.01M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement